

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1548)**

**OVERSEAS REGULATORY ANNOUNCEMENT  
UNAUDITED FINANCIAL RESULTS FOR  
THE FIRST QUARTER ENDED 31 MARCH 2022  
BY A LISTED SUBSIDIARY —  
LEGEND BIOTECH CORPORATION**

This announcement is made by the board of directors (the “**Board**”) of Genscript Biotech Corporation (the “**Company**”) pursuant to Rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Legend Biotech Corporation (“**Legend**”), a non-wholly owned subsidiary of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market in the United States, has filed a Form 6-K with the United States Securities and Exchange Commission (the “**SEC**”) in relation to the unaudited financial results of Legend for the first quarter ended 31 March 2022 and recent business highlights (“**Results**”). For details, please refer to the attached Results. The attached Results is the full Form 6-K as published on the SEC’s website available at <https://www.sec.gov/Archives/edgar/data/1801198/000115752322000714/0001157523-22-000714-index.htm>.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

**Shareholders of the Company and potential investors are advised to exercise caution in dealing in the securities of the Company.**

By order of the Board  
**GenScript Biotech Corporation**  
**MENG Jiange**  
*Chairman and Executive Director*

Hong Kong, 1 June 2022

*As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Zhang Fangliang, Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.*

\* *For identification purposes only*

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934**

**Date of Report: June 1, 2022**

**Commission File Number: 001-39307**

---

**Legend Biotech Corporation**  
(Exact Name of Registrant as Specified in its Charter)

---

**2101 Cottontail Lane  
Somerset, New Jersey 08873  
(Address of principal executive office)**

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒      Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

---

## Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights

On June 1, 2022, Legend Biotech Corporation (“Legend Biotech”) issued a press release regarding its unaudited financial results for the three months ended March 31, 2022 and recent business highlights, which is attached to this Form 6-K as Exhibit 99.1.

In addition, Legend Biotech is updating its pipeline of product candidates, as set forth in Exhibit 99.2.

This report on Form 6-K, including Exhibit 99.1 and Exhibit 99.2, is hereby incorporated by reference in the registration statements of Legend Biotech on Form F-3 (Nos. 333-257609 and 333-257625) and Form S-8 (No. 333-239478), to the extent not superseded by documents or reports subsequently filed.

### Cautionary Note Regarding Forward-Looking Statements

Statements in this report on Form 6-K about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives; statements relating to CARVYKTI™, including Legend Biotech’s expectations for CARVYKTI™, such as Legend Biotech’s manufacturing and commercialization expectations for CARVYKTI™ and the potential effect of treatment with CARVYKTI™; statements about submissions for cilta-cel to, and the progress of such submissions with, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Chinese Center for Drug Evaluation of National Medical Products Administration (CDE) and other regulatory authorities; the anticipated timing of, and ability to progress, clinical trials, including patient enrollment and the resumption of the Phase 1 clinical trial of LB1901; the ability to maintain and progress the conditional marketing authorization for cilta-cel granted by the EMA; the submission of Investigational New Drug (IND) applications to, and maintenance of such applications with, regulatory authorities; the ability to generate, analyze and present data from clinical trials; and the potential benefits of Legend Biotech’s product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; competition in general; government, industry, and general public pricing and other political pressures; the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation; as well as the other factors discussed in the “Risk Factors” section of the Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2022. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this Form 6-K as anticipated, believed, estimated or expected. Any forward-looking statements contained in this Form 6-K speak only as of the date of this Form 6-K. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

### EXHIBIT INDEX

Exhibit	Title
<a href="#">99.1</a>	<a href="#">Press Release, dated June 1, 2022</a>
<a href="#">99.2</a>	<a href="#">Pipeline</a>

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

### LEGEND BIOTECH CORPORATION

Date: June 1, 2022

By: /s/ Ying Huang  
Name: Ying Huang, Ph.D.  
Title: Chief Executive Officer

## Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights

- *The U.S. Food and Drug Administration (FDA) approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma, marking Legend Biotech's first product approved by a health authority*
- *The European Commission (EC) has granted conditional marketing authorization of CARVYKTI™ for the treatment of adults with relapsed and refractory multiple myeloma*
- *Legend Biotech engaged Ernst & Young LLP (US) as the company's auditor for the fiscal year ending December 31, 2022*
- *Legend Biotech achieved milestone payments under its collaboration agreement with Janssen Biotech, Inc. for CARVYKTI™*

SOMERSET, N.J.--(BUSINESS WIRE)--June 1, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its first quarter 2022 unaudited financial results.

“The year began with an exciting start as we received the company’s first-ever U.S. FDA approval for CARVYKTI™,” said Ying Huang, Ph.D., CEO of Legend Biotech. “This is the first of many cell therapies we hope to bring to patients, and we look forward to advancing the CARTITUDE clinical development program and our cell therapy pipeline over the rest of the year.”

### First Quarter 2022 Highlights and Recent Events

- On February 28, 2022, the U.S. Food and Drug Administration (FDA) approved CARVYKTI™ for the treatment of adults with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, marking the company’s first product approved by a health authority.
  - On May 26, 2022, the European Commission (EC) granted conditional marketing authorization of CARVYKTI™ for the treatment of adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy.
  - On April 21, 2022, Legend announced the achievement of a \$50 million milestone under its collaboration agreement with Janssen Biotech, Inc. (Janssen) for CARVYKTI™. Legend Biotech entered into an exclusive worldwide license and collaboration agreement with Janssen to develop and commercialize CARVYKTI™ in December 2017.
  - Legend Biotech engaged Ernst & Young LLP, located in the United States, as the company’s independent, registered public accounting firm for the audits of the Company’s financial statements and internal control over financial reporting for the fiscal year ending December 31, 2022.
  - CARTITUDE-6 (not yet recruiting; sponsored by the European Myeloma Network), a second Phase 3 trial in frontline multiple myeloma, was posted on clinicaltrials.gov. This Phase 3, randomized, open-label study compares daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) followed by cilta-cel vs. DVRd followed by autologous stem cell transplant (ASCT) in newly diagnosed, transplant-eligible patients with multiple myeloma.
  - On May 25, 2022, The FDA lifted its clinical hold of Legend Biotech’s Phase 1 clinical trial of LB1901, the company’s investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting malignant CD4+ T-cells for the treatment of adults with relapsed or refractory T-cell lymphoma (TCL).
  - On March 23, 2022, Legend Biotech was awarded Newcomer of the Year at the tenth annual Foreign Investment Trophy ceremony hosted by Flanders Investment & Trade (FIT) for its joint investment in a state-of-the-art manufacturing facility in Flanders with Janssen Pharmaceutica N.V.
  - Legend Biotech made the following management appointments: Lori Macomber, CPA, as Chief Financial Officer; Guowei Fang, Ph.D., as Senior Vice President, Global Head of Research and Early Development; and Marc L. Harrison, as Vice President and General Counsel.
-

**Financial Results for First Quarter Ended March 31, 2022**

*Cash and Cash Equivalents, Time Deposits, and Short-Term Investments*

As of March 31, 2022, Legend Biotech had approximately \$796.0 million of cash and cash equivalents, deposits and short-term investments.

*Revenue*

Revenue for the three months ended March 31, 2022 was \$40.8 million compared to \$13.7 million for the three months ended March 31, 2021. The increase of \$27.1 million was primarily due to revenue recognition from additional milestones achieved. Legend Biotech has not generated any revenue from product sales to date.

*Research and Development Expenses*

Research and development expenses for the three months ended March 31, 2022 were \$81.3 million compared to \$71.1 million for the three months ended March 31, 2021. This increase of \$10.2 million was primarily due to a higher number of clinical trials with more patients enrolled and a higher number of research and development activities in cilta-cel and for other pipelines in the first quarter of 2022.

*Administrative Expenses*

Administrative expenses for the three months ended March 31, 2022 were \$12.7 million compared to \$8.7 million for the three months ended March 31, 2021. The increase of \$4.0 million was primarily due to Legend Biotech’s expansion of supporting administrative functions to facilitate continuous research and development activities as well as activities to establish elements of a commercialization infrastructure.

---

#### *Selling and Distribution Expenses*

Selling and distribution expenses for the three months ended March 31, 2022 were \$21.3 million compared to \$13.4 million for the three months ended March 31, 2021. This increase of \$7.9 million was primarily due to increased costs associated with commercial preparation activities for cilta-cel.

#### *Other Income and Gains*

Other income and gains for the three months ended March 31, 2022 were \$1.0 million compared to \$0.7 million for the three months ended March 31, 2021. The increase of \$0.3 million was primarily due to more interest income earned in first quarter of 2022.

#### *Other Expenses*

Other expenses for the three months ended March 31, 2022 were \$1.5 million compared to \$2.0 million for the three months ended March 31, 2021. The decrease was primarily due to less foreign currency exchange loss in first quarter of 2022.

#### *Finance Costs*

Finance costs for the three months ended March 31, 2022 were \$1.0 million compared to \$0.04 million for the three months ended March 31, 2021. The increase was primarily due to interest for advance funding, which is comprised of interest on interest-bearing borrowings funded by Janssen under the parties' collaboration agreement.

#### *Fair Value Gain of Warrant Liability*

Fair value gain of warrant liability for the year ended March 31, 2022 was \$34.9 million caused by changes in the fair value of a warrant that Legend Biotech issued to an institutional investor through a private placement transaction in May 2021 with an initial fair value of \$81.7 million at the issuance date. The warrant was assessed as a financial liability with a fair value of \$87.9 million as of December 31, 2021 and a fair value of \$53.0 million as of March 31, 2022.

#### *Loss for the Period*

For the three months ended March 31, 2022, net loss was \$41.1 million, or \$0.13 per share, compared to a net loss of \$80.9 million, or \$0.30 per share, for the three months ended March 31, 2021.

#### **About Legend Biotech**

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell, T-cell receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide.

---



**About CARVYKTI™ (Ciltacabtagene autoleucel; cilta-cel)**

CARVYKTI™ is a BCMA-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient’s own T-cells with a transgene encoding a chimeric antigen receptor (CAR) that identifies and eliminates cells that express BCMA. BCMA is primarily expressed on the surface of malignant multiple myeloma B-lineage cells, as well as late-stage B-cells and plasma cells. The CARVYKTI™ CAR protein features two BCMA-targeting single domain antibodies designed to confer high avidity against human BCMA. Upon binding to BCMA-expressing cells, the CAR promotes T-cell activation, expansion, and elimination of target cells.<sup>1</sup>

In December 2017, Legend Biotech Corporation entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize cilta-cel.

In February 2022, CARVYKTI™ was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with relapsed or refractory multiple myeloma.<sup>2</sup> In May 2022, the European Commission (EC) granted conditional marketing authorization of CARVYKTI™ for the treatment of adults with relapsed and refractory multiple myeloma.<sup>3</sup> Cilta-cel was granted Breakthrough Therapy Designation in the U.S. in December 2019 and in China in August 2020. In addition, cilta-cel received a PRIority MEdicines (PRIME) designation from the European Commission in April 2019. Cilta-cel also received Orphan Drug Designation from the U.S. FDA in February 2019, from the European Commission in February 2020, and from the Pharmaceuticals and Medicinal Devices Agency (PMDA) in Japan in June 2020. In May 2022, the European Medicines Agency’s Committee for Orphan Medicinal Products recommended by consensus that the orphan designation for cilta-cel be maintained on the basis of clinical data demonstrating improved and sustained complete response rates following treatment.<sup>4</sup>

**About Multiple Myeloma**

Multiple myeloma is an incurable blood cancer that starts in the bone marrow and is characterized by an excessive proliferation of plasma cells.<sup>5</sup> In 2022, it is estimated that more than 34,000 people will be diagnosed with multiple myeloma, and more than 12,000 people will die from the disease in the U.S.<sup>6</sup> While some patients with multiple myeloma have no symptoms at all, most patients are diagnosed due to symptoms that can include bone problems, low blood counts, calcium elevation, kidney problems or infections.<sup>7</sup> Although treatment may result in remission, unfortunately, patients will most likely relapse.<sup>8</sup> Patients who relapse after treatment with standard therapies, including protease inhibitors, immunomodulatory agents, and an anti-CD38 monoclonal antibody, have poor prognoses and few treatment options available.<sup>9,10</sup>

---

**Cautionary Note Regarding Forward-Looking Statements**

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives; statements relating to CARVYKTI™, including Legend Biotech’s expectations for CARVYKTI™, such as Legend Biotech’s manufacturing and commercialization expectations for CARVYKTI™ and the potential effect of treatment with CARVYKTI™; statements about submissions for cilta-cel to, and the progress of such submissions with, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Chinese Center for Drug Evaluation of National Medical Products Administration (CDE) and other regulatory authorities; the anticipated timing of, and ability to progress, clinical trials, including patient enrollment and the resumption of the Phase 1 clinical trial of LB1901; the ability to maintain and progress the conditional marketing authorization for cilta-cel granted by the EMA; the submission of Investigational New Drug (IND) applications to, and maintenance of such applications with, regulatory authorities; the ability to generate, analyze and present data from clinical trials; and the potential benefits of Legend Biotech’s product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; competition in general; government, industry, and general public pricing and other political pressures; the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation; as well as the other factors discussed in the “Risk Factors” section of the Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2022. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

---

**LEGEND BIOTECH CORPORATION**  
**CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS**

(in thousands, US\$, except share and per share data)	Three months ended March 31	
	2022 (Unaudited)	2021 (Unaudited)
<b>REVENUE</b>	40,827	13,682
Other income and gains	1,012	722
Research and development expenses	(81,346)	(71,072)
Administrative expenses	(12,657)	(8,742)
Selling and distribution expenses	(21,302)	(13,417)
Other expenses	(1,527)	(2,034)
Fair value gain of warrant liability	34,900	-
Finance costs	(994)	(38)
<b>LOSS BEFORE TAX</b>	<b>(41,087)</b>	<b>(80,899)</b>
Income tax expense	-	-
<b>LOSS FOR THE PERIOD</b>	<b>(41,087)</b>	<b>(80,899)</b>
Attributable to:		
Ordinary equity holders of the parent	<b>(41,087)</b>	<b>(80,899)</b>
Loss per share attributable to ordinary equity holders of the parent:		
Ordinary shares – basic	(0.13)	(0.30)
Ordinary shares – diluted	<b>(0.13)</b>	<b>(0.30)</b>
Shares used in loss per share computation:		
Ordinary shares – basic	308,699,034	266,293,913
Ordinary shares – diluted	<b>308,699,034</b>	<b>266,293,913</b>

**LEGEND BIOTECH CORPORATION**  
**CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**

	March 31, 2022 (Unaudited)	December 31, 2021
<b>(in thousands, US\$)</b>		
<b>NON-CURRENT ASSETS</b>		
Property, plant and equipment	156,005	145,724
Advance payments for property, plant and equipment	258	2,168
Right-of-use assets	7,393	7,186
Other non-current assets	4,912	5,148
Intangible assets	4,517	4,684
Time deposits	4,726	4,705
	<b>177,811</b>	<b>169,615</b>
Total non-current assets		
<b>CURRENT ASSETS</b>		
Inventories	2,895	1,749
Trade receivables	50,451	50,410
Prepayments, other receivables and other assets	16,651	12,754
Financial assets measured at amortized cost	29,974	29,937
Financial assets at fair value through profit or loss	99,995	-
Pledged deposits	1,448	1,444
Time deposits	283,505	163,520
Cash and cash equivalents	377,786	688,938
	<b>862,705</b>	<b>948,752</b>
Total current assets		
Total assets	<b>1,040,516</b>	<b>1,118,367</b>
<b>CURRENT LIABILITIES</b>		
Trade and notes payables	9,712	7,043
Other payables and accruals	96,055	123,464
Government grants	320	304
Warrant liability	53,000	87,900
Lease liabilities	883	911
Contract liabilities	65,560	60,644
	<b>225,530</b>	<b>280,266</b>
Total current liabilities		
<b>NON-CURRENT LIABILITIES</b>		
Contract liabilities	245,850	242,578
Lease liabilities	1,630	1,593
Interest-bearing loans and borrowings	126,714	120,462
Other non-current liabilities	356	396
Government grants	1,873	1,866

	March 31, 2022 (Unaudited)	December 31, 2021
(in thousands, US\$)		
Total non-current liabilities	376,423	366,895
Total liabilities	601,953	647,161
EQUITY		
Share capital	31	31
Reserves	438,532	471,175
Total ordinary shareholders' equity	438,563	471,206
Total equity	438,563	471,206
Total liabilities and equity	1,040,516	1,118,367

**LEGEND BIOTECH CORPORATION**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

(in thousands, US\$)	Three months ended March 31	
	2022 (Unaudited)	2021 (Unaudited)
<b>LOSS BEFORE TAX</b>	(41,087)	(80,899)
<b>CASH FLOWS USED IN OPERATING ACTIVITIES</b>	(78,687)	(26,787)
<b>CASH FLOWS USED IN INVESTING ACTIVITIES</b>	(232,500)	(17,150)
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>	25	207
<b>NET DECREASE IN CASH AND CASH EQUIVALENTS</b>	(311,162)	(43,730)
Effect of foreign exchange rate changes, net	10	337
Cash and cash equivalents at beginning of the period	688,938	455,689
<b>CASH AND CASH EQUIVALENTS AT END OF THE PERIOD</b>	<b>377,786</b>	<b>412,296</b>
<b>ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS</b>		
Cash and bank balances	667,465	462,552
Less: Pledged deposits	1,448	256
Time deposits	288,231	50,000
Cash and cash equivalents as stated in the statement of financial position	377,786	412,296
Cash and cash equivalents as stated in the statement of cash flows	377,786	412,296

---

<sup>1</sup> CARVYKTI™ Prescribing Information. Horsham, PA: Janssen Biotech, Inc.

<sup>2</sup> CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma. Available at: <https://legendbiotech.com/wp-content/uploads/2022/02/CARVYKTI%E2%84%A2-ciltacabtagene-autoleucel-BCMA-Directed-CAR-T-Therapy-Receives-U.S.-FDA-Approval-2.pdf>. Last accessed: May 2022.

<sup>3</sup> CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma. Available at: <https://investors.legendbiotech.com/node/7431/pdf>. Last accessed: May 2022.

<sup>4</sup> European Commission. Community Register of Orphan Medicinal Products. Available at: <https://ec.europa.eu/health/documents/community-register/html/o2252.htm>. Last accessed: May 2022.

<sup>5</sup> American Society of Clinical Oncology. Multiple myeloma: introduction. Available at: <https://www.cancer.net/cancer-types/multiple-myeloma/introduction> . Last accessed: May 2022.

<sup>6</sup> American Cancer Society. "Key Statistics About Multiple Myeloma." Available at: <https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html>. Last accessed: May 2022.

<sup>7</sup> American Cancer Society. Multiple myeloma: early detection, diagnosis and staging. Available at: <https://www.cancer.org/content/dam/CRC/PDF/Public/8740.00.pdf>. Last accessed May 2022.

<sup>8</sup> Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5),548-567. doi:10.1002/ajh.25791.

<sup>9</sup> Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11):2443- 2448.

<sup>10</sup> Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38- targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266-2275.

## Contacts


### Investor:

Joanne Choi, Senior Manager, Investor Relations, Legend Biotech  
[joanne.choi@legendbiotech.com](mailto:joanne.choi@legendbiotech.com)

Crystal Chen, Manager, Investor Relations, Legend Biotech  
[crystal.chen@legendbiotech.com](mailto:crystal.chen@legendbiotech.com)

### Press:

Tina Carter, Corporate Communications Lead, Legend Biotech  
[tina.carter@legendbiotech.com](mailto:tina.carter@legendbiotech.com)  
(908) 331-5025



ALL, Acute lymphoblastic leukemia; BCMA, B-cell maturation antigen; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like ligand 3; GPC3, Glypican-3; HCC, hepatocellular carcinoma; HIV, human immunodeficiency virus; IT, investigator-initiated trial; NHL, non-Hodgkin lymphomas; MM, multiple myeloma; NSCLC, non small cell lung cancer; SCLC, small cell lung cancer; TCL, T-cell lymphoma  
<sup>1</sup>In collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson. <sup>2</sup>Phase 1 IT in China. <sup>3</sup>Multiple allogeneic platforms are being developed.